Catalyst Pharmaceuticals Seen 43% Upside with $34.86 Mean Price Target
Catalyst Pharmaceuticals shares have risen 1.7% over the past month to $24.32 and carry a mean analyst price target of $34.86, implying a 43.3% upside. Analyst targets range from $32 to $38 (SD $1.95) and the Zacks Consensus for 2026 EPS was raised 13% in 30 days.
1. Analyst Price Targets and Price Performance
Over the past four weeks, Catalyst Pharmaceuticals shares have climbed 1.7% to close at $24.32. Wall Street’s seven short-term price targets average $34.86, suggesting a 43.3% upside, with low dispersion (standard deviation of $1.95) across estimates ranging from $32 to $38.
2. Earnings Revisions and Zacks Rank
In the last 30 days, the Zacks Consensus Estimate for 2026 EPS was revised up by 13%, reflecting three upward revisions and no downgrades. Catalyst holds a Zacks Rank #1 (Strong Buy), positioning it among the top 5% of over 4,000 rated stocks based on earnings estimate momentum and other factors.